Therefore, they, especially mutations, can serve as therapeutic targets.34 In most advanced NSCLC patients, EGFR mutations primarily consist of exon 19 deletions (accounting for 45%) and the L858R mutation (accounting for 40%), either alone or in combination with other mutations.35 These mutations are particularly prevalent among Asian women with adenocarcinoma who have either never smoked or have a history of mild smoking. This evidence concerns the gene EGFR and adenocarcinoma.